# A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Source: https://onco.cc/trials/nct07171606/  
OnCo record `nct07171606` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SSGJ-706, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.

## Summary

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients is a phase 2 interventional study registered as NCT07171606 by Shenyang Sunshine Pharmaceutical Co., LTD., with 240 participants planned, started 2025-10-24 and due to reach its primary completion in 2026-08-31. Interventions recorded: SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel and PD-1 Inhibitor + Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07171606
- Phase: 2
- Setting: A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
- Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT07171606: https://clinicaltrials.gov/study/NCT07171606

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/)

---
JSON: https://onco.cc/api/v1/entities/nct07171606.json